Table 3 Treatment cascade outcomes
From: A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa
Indicator | Target reached (n) | % | 95% CI |
|---|---|---|---|
Baseline | |||
HCV Viremic | 116 | ||
Treatment Eligible | 94 | 81.0% | 72.7–87.7% |
Antiretroviral therapy less than 3 months | 18 | 82.8% | 9.5–23.4% |
Anti-HBV therapy less than 3 months | 1 | 9.1% | 0.0–4.7% |
Not Interested in direct-acting antiviral therapy | 1 | 4.6% | 0.0–4.7% |
Viremic Lost to Follow-Up | 2 | 9.1% | 2.1–6.1% |
Treatment Initiated | 87 | 91.6% | 84.1–96.3% |
Eligible Lost to Follow-Up | 6 | 6.4% | 2.4–13.4% |
Not Interested in direct-acting antiviral therapy | 1 | 1.1% | 0.0–5.8% |
4-Week Treatment Visit | |||
4-Week Treatment Completed | 84 | 96.6% | 90.2–99.3% |
HCV Viral Load 4 weeks | 67 | 88.2% | 78.7–94.4% |
8-Week Treatment Visit | |||
8-Week Treatment Completed | 79 | 94.0% | 86.6–98.0% |
End of Treatment Visit | |||
Treatment Complete | 75 | 94.9% | 87.5–98.6% |
End of Treatment Plasma Specimen | 66 | 94.3% | 86.0 – 98.4% |
HCV Viral Load Suppressed End of Treatment | 61 | 92.4% | 83.2–97.5% |
12 Weeks Post-End of Treatment Visit | |||
12 Weeks Post-End of Treatment Plasma Specimen | 57 | 93.4% | 84.1–98.2% |
Sustained Virological Response | 51 | 89.5% | 78.5–96.0% |
Ad Hoc Follow-Up | |||
Reinfection | 7 | 12.5% | 5.2–24.1% |
Overall | |||
Missed Doses < 7 days | 15 | 17.2% | 10.0–26.8% |
Adverse Events at Any Time | 5 | 6.0% | 2.7–14.9% |
Abdominal Discomfort | 2 | 2.3% | 0.3–8.1% |
Reflux | 1 | 1.2% | 0.0–6.2% |
Headache | 1 | 1.2% | 0.0–6.2% |
Sleep Disturbance | 1 | 1.2% | 0.0–6.2% |
Loss to Follow-Up > 90 days | 33 | 37.9% | 27.7–49.0% |